|
[1]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.
|
|
[2] WHO Guidelines Approved by the Guidelines Review Committee.Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection[J].Geneva:World Health Organization, 2015.
|
|
[3]SARIN SK, KUMAR M, LAU GK, et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update[J].Hepatol Int, 2016, 10 (1) :1-98.
|
|
[4]TERRAULT NA, BZOEEJ NH, CHANG KM, et al.AASLD guidelines for treatment of chronic hepatitis B[J].Hepatology, 2016, 63 (1) :261-283.
|
|
[5]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol, 2012, 57 (1) :167-185.
|
|
[6] LIAW YF.Natural history of chronic hepatitis B virus infection and long-term outcome under treatment[J].Liver Int, 2009, 29 (Suppl 1) :100-107.
|
|
[7]ANDREANI T, SERFATY L, MOHAND D, et al.Chronic hepatitis B virus carriers in the immune tolerant phase of infection:histologic findings and outcome[J].Clin Gastroenterol Hepatol, 2007, 5 (5) :636-641.
|
|
[8]TSEN TC, KAO JH.Treating immune-tolerant hepatitis B[J].J Viral Hepat, 2015, 22 (2) :77-84.
|
|
[9]LIU CJ, KAO JH.Global perspective on the natural history of chronic hepatitis B:role of hepatitis B virus genotypes A to J[J].Semin Liver Dis, 2013, 33 (2) :97-102.
|
|
[10]CHEN CJ, YANG HI, SU J, et al.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J].JAMA, 2006, 295 (1) :65-73.
|
|
[11]ILOEJE UH, YANG HI, SU J, et al.Predicting cirrhosis risk based on the level of circulating hepatitis B viral load[J].Gastroenterology, 2006, 130 (3) :678-686.
|
|
[12]YOTSUYANAGI H, ITO K, YAMADA N, et al.High levels of hepatitis B virus after the onset of disease lead to chronic infection in patients with acute hepatitis B[J].Clin Infect Dis, 2013, 57 (7) :935-942.
|
|
[13]LAU G, MARCELLIN P, PETERS M.Chronic hepatitis B:a global health problem requiring coherent worldwide treatment strategies[J].Hepatol Int, 2007, 1 (2) :316-325.
|
|
[14]CHU CM, LIAW YF.Chronic hepatitis B virus infection acquired in childhood:special emphasis on prognostic and therapeutic implication of delayed HBe Ag seroconversion[J].J Viral Hepat, 2007, 14 (3) :147-152.
|
|
[15]LIAW YF.Hepatitis flares and hepatitis B e antigen seroconversion:implication in anti-hepatitis B virus therapy[J].J Gastroenterol Hepatol, 2003, 18 (3) :246-252.
|
|
[16]CHU CM, HUNG SJ, LIN J, et al.Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels[J].Am J Med, 2004, 116 (12) :829-834.
|
|
[17]FUNG J, SETO WK, LAI CL, et al.Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B:implications for antiviral therapy[J].J Hepatol, 2011, 54 (2) :195-200.
|
|
[18]CHU CJ, HUSSAIN M, LOK AS.Hepatitis B virus genotype B is associated with earlier HBe Ag seroconversion compared with hepatitis B virus genotype C[J].Gastroenterology, 2002, 122 (7) :1756-1762.
|
|
[19]CHU CM, LIAW YF.Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B[J].J Hepatol, 2005, 43 (3) :411-417.
|
|
[20]WATANABE K, TAKAHASHI T, TAKAHASHI S, et al.Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations[J].J Gastroenterol Hepatol, 2005, 20 (3) :441-449.
|
|
[21]LAU GK, WANG FS.Uncover the immune biomarkers underlying hepatitis B e antigen (HBe Ag) seroconversion:a need for more translational study[J].J Hepatol, 2012, 56 (4) :753-755.
|
|
[22]KIM HC, NAM CM, JEE SH, et al.Normal serum aminotransferase concentration and risk of mortality from liver diseases:prospective cohort study[J].BMJ, 2004, 328 (7446) :983.
|
|
[23]LAI M, HYATT BJ, NASSER I, et al.The clinical significance of persistently normal ALT in chronic hepatitis B infection[J].J Hepatol, 2007, 47 (6) :760-767.
|
|
[24]HUI CK, LEUNG N, YUEN ST, et al.Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase[J].Hepatology, 2007, 46 (2) :395-401.
|
|
[25]LESMANA CR, GANI RA, HASAN I, et al.Significant hepatic histopathology in chronic hepatitis B patients with serum ALT less than twice ULN and high HBV-DNA levels in Indonesia[J].J Dig Dis, 2011, 12 (6) :476-480.
|
|
[26]KUMAR M, SARIN SK.Hepatitis B virus immune tolerant patients:need to differentiate patients with or without liver disease[J].Gastroenterology, 2009, 137 (2) :742-743.
|
|
[27]CROAGH CM, LUBEL JS.Natural history of chronic hepatitis B:phases in a complex relationship[J].World J Gastroenterol, 2014, 20 (30) :10395-10404.
|
|
[28]TOHME RA, BULKOW L, HOMAN CE, et al.Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001-2010[J].J Clin Virol, 2013, 58 (2) :396-400.
|
|
[29]MCMAHONB J, BULKOW L, SIMONS B, et al.Relationship between level of hepatitis B virus DNA and liver disease:a population-based study of hepatitis B e antigen-negative persons with hepatitis B[J].Clin Gastroenterol Hepatol, 2014, 12 (4) :701-706.
|
|
[30]PAPATHEODORIDIS GV, MANOLAKOPOULOS S, LIAW YF, et al.Follow-up and indications for liver biopsy in HBe Ag-negative chronic hepatitis B virus infection with persistently normal ALT:a systematic review[J].J Hepatol, 2012, 57 (1) :196-202.
|
|
[31]ILOEJE UH, YANG HI, SU J, et al.Viral load not serum ALT is the primary predictor of progression to cirrhosis in persons chronically infected with HBV:results from a long-term prospective study[J].J Hepatol, 2005, 42:s180.
|
|
[32]ZENG QL, LI CX, XU GH, et al.Misdiagnosis of immune phases in HBe Ag-positive chronic hepatitis B virus infection[J].Chin J Clin Infect Dis, 2016, 9 (1) :59-61. (in Chinese) 曾庆磊, 李春霞, 徐光华, 等.HBe Ag阳性慢性HBV感染者免疫耐受期和免疫清除期的误判[J].中华临床感染病杂志, 2016, 9 (1) :59-61.
|
|
[33]PAPATHEODORIDIS GV.Hepatitis B virus treatment:which patients can have treatment deferred?[J].Clin Liver Dis, 2013, 2 (1) :15-17.
|
|
[34]KUMAR M, SARIN SK, HISSAR S, et al.Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT[J].Gastroenterology, 2008, 134 (5) :1376-1384.
|
|
[35]DEGERTEKIN B, LOK A.Should liver biopsies be performed on all hepatitis B carriers?[J].Gastroenterology, 2008, 135 (5) :1802.
|
|
[36]WANG CC, LIM LY, DEUBNER H, et al.Factors predictive of significant hepatic fibrosis in adults with chronic hepatitis B and normal serum ALT[J].J Clin Gastroenterol, 2008, 42 (7) :820-826.
|
|
[37]WONG GL, CHAN HL, YU Z, et al.Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen:a prospective cohort study with paired transient elastography examination[J].J Gastroenterol Hepatol, 2013, 28 (11) :1762-1769.
|
DownLoad: